PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 132 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $44,019 | -39.6% | 2,639 | 0.0% | 0.00% | -100.0% |
Q2 2023 | $72,889 | +154983.0% | 2,639 | +28.8% | 0.00% | – |
Q1 2023 | $47 | +113.6% | 2,049 | 0.0% | 0.00% | – |
Q4 2022 | $22 | -99.9% | 2,049 | +2.4% | 0.00% | – |
Q3 2022 | $16,000 | 0.0% | 2,000 | 0.0% | 0.00% | – |
Q2 2022 | $16,000 | -97.4% | 2,000 | -92.4% | 0.00% | -100.0% |
Q1 2022 | $625,000 | -21.4% | 26,390 | -2.8% | 0.00% | -33.3% |
Q4 2021 | $795,000 | +9837.5% | 27,150 | +5933.3% | 0.01% | – |
Q3 2021 | $8,000 | -60.0% | 450 | 0.0% | 0.00% | – |
Q2 2021 | $20,000 | +66.7% | 450 | 0.0% | 0.00% | – |
Q1 2021 | $12,000 | +33.3% | 450 | 0.0% | 0.00% | – |
Q4 2020 | $9,000 | – | 450 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |